53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) CHICAGO – In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of myeloma upon receiving a new type of immunotherapy ̶ chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA. Most patients had only mild side effects. The study was presented at the 2017 American Society of Clinical Oncology (ASCO) Annual…
53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago – According to Phase 3 ‘482 study, the largest international multiple myeloma trial ever conducted with 1,718 patients involved, patients who receive denosumab (XGEVA) had a significantly lower rate of renal adverse events compared to zoledronic acid (10.0 percent versus 17.1 percent, p<0.001).…
53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) June, 2, 2017 CHICAGO – About 50% of all cancer survivors report moderate to high fear of recurrence. The fear can be so distressing that it negatively affects medical follow-up behavior, mood, relationships, work, goal setting, and quality of life, according to a study presented…
We all were saddened to hear of our recent loss of Yacob Yacobovitch, who passed away on the 18th of april 2017. Yacob Yacobovitch was member of Myeloma Patients Europe from 2012 until 2016.
Patients suffering from rare blood disorders will benefit from networks of excellence across the European Member States. At the third conference on European Reference Networks (ERNs) this month in Vilnius, Lithuania, EuroBloodNet was officially announced as one of the recently approved ERNs.
PHOENIX – Mayo Clinic researchers have found that an experimental drug, LCL161, stimulates the immune system, leading to tumor shrinkage in patients affected by myeloma. The findings are published in Nature Medicine. Myeloma is a blood cancer that affects plasma cells – white blood cells that normally produce antibodies to fight infection. Rather than produce…
It is with great sadness that we share with you that our friend, colleague and Board member Mika Peltovaara (23 Dec 1965 – 21 Febr 2017) passed away in the morning of the 21th of February 2017. Mika was board member of Myeloma Patients Europe since 2014. He was a very experienced, long-serving patient advocate…
Amsterdam, The Netherlands. Cancer patients are living longer and in many cases the disease is becoming chronic rather than acute. Access to drugs that help extend life and improve quality of life, and fair prices for those drugs are therefore essential for more and more people. But patients are badly served in this respect, with…
